BACKGROUND: Pathogen reduction in platelet concentrates (PC) using Amotosalen/UVA-light reduces the risk of transfusion transmitted infections but also decreases the post-transfusion platelet count increment. Little is known about potential platelet lesions caused by Amotosalen/UVA-light, which may reduce therapeutic efficacy of PCs. METHODS: Platelets from buffy coat (n=15) derived PCs were pooled and split into three equal PC-units. PC-1 was left untreated (control). PC-2 was Amotosalen/UVA treated using the INTERCEPT Blood System(™), PC-3 was gamma irradiated (30 Gy). Samples were prepared one and five days after PC-production for LC-ESI-MS/MS analysis. Proteins displaying treatment-dependent changes in intensity were classified according to Gene Ontology. RESULTS: In total, 948 proteins were identified, 721 with ≥2 peptides. At day 1, Amotosalen/UVA-treatment triggered alteration of 23 proteins, and gamma irradiation of 49 proteins (overlap: 11 proteins). Five days storage revealed 58 (Amotosalen/UVA treated), 50 (gamma irradiated), and 36 (controls) changes in the platelet proteome compared to control platelets at day 1. Gene Ontology analysis revealed that many affected proteins were displaying specific catalytic activities and/or protein/nucleic acid binding capacity. We identified platelet endothelial aggregation receptor 1 precursor, chloride intracellular channel protein 4, and protein-tyrosine sulfotransferase 2 as proteins uniquely and consistently altered after treatment and storage of Amotosalen/UVA treated platelets. CONCLUSION: While Amotosalen/UVA-treatment causes less pronounced proteome changes than gamma irradiation at day 1, our data indicate an increase in storage lesions at day 5 caused by this pathogen reduction treatment.
BACKGROUND: Pathogen reduction in platelet concentrates (PC) using Amotosalen/UVA-light reduces the risk of transfusion transmitted infections but also decreases the post-transfusion platelet count increment. Little is known about potential platelet lesions caused by Amotosalen/UVA-light, which may reduce therapeutic efficacy of PCs. METHODS: Platelets from buffy coat (n=15) derived PCs were pooled and split into three equal PC-units. PC-1 was left untreated (control). PC-2 was Amotosalen/UVA treated using the INTERCEPT Blood System(™), PC-3 was gamma irradiated (30 Gy). Samples were prepared one and five days after PC-production for LC-ESI-MS/MS analysis. Proteins displaying treatment-dependent changes in intensity were classified according to Gene Ontology. RESULTS: In total, 948 proteins were identified, 721 with ≥2 peptides. At day 1, Amotosalen/UVA-treatment triggered alteration of 23 proteins, and gamma irradiation of 49 proteins (overlap: 11 proteins). Five days storage revealed 58 (Amotosalen/UVA treated), 50 (gamma irradiated), and 36 (controls) changes in the platelet proteome compared to control platelets at day 1. Gene Ontology analysis revealed that many affected proteins were displaying specific catalytic activities and/or protein/nucleic acid binding capacity. We identified platelet endothelial aggregation receptor 1 precursor, chloride intracellular channel protein 4, and protein-tyrosine sulfotransferase 2 as proteins uniquely and consistently altered after treatment and storage of Amotosalen/UVA treated platelets. CONCLUSION: While Amotosalen/UVA-treatment causes less pronounced proteome changes than gamma irradiation at day 1, our data indicate an increase in storage lesions at day 5 caused by this pathogen reduction treatment.
Authors: Peter Schubert; Brankica Culibrk; Danielle Coupland; Ken Scammell; Maria Gyongyossy-Issa; Dana V Devine Journal: Transfusion Date: 2011-08-09 Impact factor: 3.157
Authors: Peter Schlenke; Wibke Hagenah; Johannes Irsch; David Sundin; Laurence Corash; Lily Lin; Holger Kirchner; Thomas Wagner Journal: Ann Hematol Date: 2011-04-19 Impact factor: 3.673
Authors: Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan Journal: Blood Date: 2004-05-11 Impact factor: 22.113
Authors: Harald Mohr; Leif Steil; Ute Gravemann; Thomas Thiele; Elke Hammer; Andreas Greinacher; Thomas H Müller; Uwe Völker Journal: Transfusion Date: 2009-08-04 Impact factor: 3.157
Authors: Andrew D Johnson; Lisa R Yanek; Ming-Huei Chen; Nauder Faraday; Martin G Larson; Geoffrey Tofler; Shiow J Lin; Aldi T Kraja; Michael A Province; Qiong Yang; Diane M Becker; Christopher J O'Donnell; Lewis C Becker Journal: Nat Genet Date: 2010-06-06 Impact factor: 38.330
Authors: Friedgard Julmy; Roland A Ammann; Stefano Fontana; Behrouz Mansouri Taleghani; Andreas Hirt; Kurt Leibundgut Journal: Transfus Med Hemother Date: 2014-05-12 Impact factor: 3.747
Authors: Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap Journal: Transfusion Date: 2013-01 Impact factor: 3.157
Authors: Julia Hoefer; Markus Luger; Christian Dal-Pont; Zoran Culig; Harald Schennach; Stefan Jochberger Journal: Front Aging Neurosci Date: 2017-12-01 Impact factor: 5.750